Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)

NCT03920072 is registered in ClinicalTrials.gov with Kyowa Kirin Pharmaceutical Development Ltd as lead sponsor.

NCT NCT03920072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03920072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
Lead sponsor
Kyowa Kirin Pharmaceutical Development Ltd
Phase
Phase 3
Overall status
Completed
Start date
March 7, 2019
Completion date
April 7, 2022
Enrollment
35 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked hypophosphatemia